Lucentis, developed by San Francisco-based Genentech, is intended to treat individuals with wet age-related macular degeneration and macular edema after retinal vein occlusion — two eye conditions that can impair vision and lead to blindness, according to the report.
The prefilled syringe cuts several steps out of the preparation and administration process for physicians, according to the report.
Genentech expects it to hit the market in early 2017.
More articles on supply chain:
Trucking industry provides less financial support to Donald Trump than past Republican nominees: 4 things to know
Drug industry, hospitals fight over 340B drug pricing program
6 latest FDA approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.